Purpose P-glycoprotein limits the tissue penetration of many antiretroviral drugs. The aim of our study was to characterize the effects of the P-glycoprotein substrate cyclosporin A on T cell P-glycoprotein activity in human immunodeficiency virus-infected participants in the AIDS Clinical Trials Group study A5138. Methods We studied P-glycoprotein activity on CD4 and CD8 T cells in 16 participants randomized to receive oral cyclosporin A (n = 9) or not (n = 7) during initiation antiretroviral therapy (ART) that did not include protease or non-nucleoside reverse transcriptase inhibitors. Results CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001). Plasma trough cyclosporin A concentrations correlated with the change in P-glycoprotein activity in several T cell subsets. Conclusions Oral cyclosporin A can inhibit peripheral blood CD4 T cell P-glycoprotein activity. Targeted Pglycoprotein inhibition may enhance the delivery of ART to T cells.
Introduction P-glycoprotein, the efflux transporter encoded by ABCB1, limits drug entry into tissues and cells [1, 2] . Inhibition of P-glycoprotein may enhance the penetration of substrate drugs [3, 4] . The role of P-glycoprotein during human immunodeficiency virus (HIV) therapy has been attracting interest [5] because protease inhibitors (PIs) and other antiretrovirals are P-glycoprotein substrates [6] [7] [8] [9] and Pglycoprotein expression on CD4 T lymphocytes could decrease antiviral effects [10] [11] [12] . Protease inhibitors can inhibit P-glycoprotein activity [13] [14] [15] , but increased cellular P-glycoprotein expression can be induced ex vivo by PIs or non-nucleoside reverse transcriptase inhibitors (NNRTIs) [16] [17] [18] [19] . Limited data also suggest that Pglycoprotein overexpression in cell lines may influence HIV-associated effects, conferring relative resistance to infection [20, 21] and apoptosis [22, 23] . An ABCB1 polymorphism that affects P-glycoprotein expression [24] may predict more favorable virologic responses to antiretroviral therapy (ART) [25] [26] [27] and/or decreased drug toxicity [28, 29] , although available data are conflicting.
Targeted P-glycoprotein inhibition has been pursued as a strategy to restore the susceptibility of multidrug resistant cancer cells to chemotherapy [30] [31] [32] [33] . The immunosuppressant drug, cyclosporin A, inhibits P-glycoprotein activity [34, 35] , which may explain in part the increased oral bioavailability of some chemotherapeutic agents with concomitant cyclosporin administration [36] . The administration of oral cyclosporin A increased plasma levels (trough and area-under-the-curve) of the HIV PI nelfinavir in a single study of seven HIV-infected subjects [37] .
Immune activation during HIV infection predicts disease progression [38, 39] , suggesting that immunosuppressive therapy may paradoxically be beneficial during ART. The AIDS Clinical Trials Group (ACTG) study A5138 tested the hypothesis that concomitant cyclosporin A would enhance immune reconstitution during ART initiation. Although no sustained effects were seen [40] , study A5138 provided an opportunity to assess the impact of cyclosporin A on P-glycoprotein activity during ART initiation. The ART regimens during the first 14 days of study A5138 included neither PIs nor NNRTIs that could affect P-glycoprotein activity. We hypothesized that cyclosporin A would inhibit peripheral blood T cell Pglycoprotein activity. The objective of this study was to determine the effects of cyclosporin A on T cell Pglycoprotein efflux activity ex vivo using specimens from the participants in a clinical trial who were receiving PI and NNRTI-sparing ART in the presence and absence of cyclosporin A.
Methods

ACTG protocol A5138
Primary results from study A5138 have been reported [40] . Briefly, ART-naïve HIV-infected individuals were started on twice-daily co-formulated abacavir/zidovudine/lamivudine. During the first 14 days of ART, the participants were randomized to also receive either cyclosporin A (Neoral; Sandoz, Basel, Switzerland) 4 mg/kg twice daily or no cyclosporin A. On day 15, all participants added efavirenz 600 mg once daily to their therapeutic regimen. Trough cyclosporin A concentrations were obtained at days 3, 7, 10, and 14. The primary study was registered as trial NCT00031070 (http://www.clinicaltrials.gov). The protocol and all substudies of this primary study were approved by local Institutional Review Boards at each clinical trial site. All participants in this substudy provided written informed consent under the A5138 protocol version that included Pglycoprotein assays.
Dye efflux assay
Acid-citrate-dextrose (ACD)-anticoagulated whole blood was shipped to Vanderbilt University at ambient temperature and assayed within 24 h of phlebotomy. Three specimens not processed within 24 h were not analyzed. The activity of P-glycoprotein in peripheral blood T cells was determined by measuring the cellular efflux of the fluorescent P-glycoprotein substrate 3,3′-diethyloxacarbocyanine iodide [DiOC 2 (3)] as described elsewhere [13, 41] . The cellular efflux of DiOC 2 (3), which is a specific Pglycoprotein substrate [42] , has been demonstrated to be directly related to functional P-glycoprotein in these cells [43, 44] . Briefly, CD4
+ and CD8 + T cells were loaded with DiOC 2 (3) by incubating 1 ml of ACD-anti-coagulated whole blood with 1 mL of 100 nM DiOC 2 (3) in phosphate buffered saline (PBS) for 15 min at 37°C. Cells were collected by centrifugation, washed with ice-cold PBS, and resuspended in 600 μL of RPMI 1640 plus 50 mM HEPES (pH 7.4). Verapamil was added to one-half of each sample to a final concentration of 19 μM, resulting in greater than 95% inhibition of the cellular efflux of DiOC 2 (3) by Pglycoprotein. A 100-μL aliquot of each sample, plus or minus verapamil, was then added in duplicate to each well of a 96-deep-well microplate. For each microplate, a sample from one of six healthy adults with previously determined P-glycoprotein activity was included as an assay control. The microplate was then incubated at 37°C for 60 min. After incubation, T cells were labeled with fluorochromeconjugated monoclonal antibodies (CD62L-PE, CD45RA-APC, and CD4-PerCP-Cy5.5 or CD8-PerCP-Cy5.5) for 30 min on ice. Erythrocytes were lysed with Optilyse B essentially as described by the manufacturer (Immunotech, Marseille, France), and the leukocytes were pelleted by centrifugation, washed with ice-cold PBS, and fixed with 2% paraformaldehyde in PBS prior to analysis by flow cytometry.
Flow cytometry analysis T cell DiOC 2 (3) content was quantified using a FACSCalibur flow cytometer fitted with a Multiwell AutoSampler (Becton Dickinson, San Jose, CA). For each sample, data from at least 10,000 electronically gated lymphocytes were collected. Fluorescence of DiOC 2 (3) was detected following excitation at 488 nm, through a 530 nm band-pass filter. The data were analyzed with WinMDI software ver. 2.8 (J. Trotter, The Scripps Institute, La Jolla, CA). Naive T cells were defined by surface staining for both CD45RA and CD62L (L-selectin). The percentage of the total and naïve CD4 + or CD8 + T cells that were dim (dye efflux positive) was determined by gating on parallel control samples with near complete P-glycoprotein inhibition (>95%) by verapamil, as illustrated in Fig. 1 . For each subject, net dye efflux (P-glycoprotein activity) was reported as the percentage of dim cells after subtracting the background dim cell percentage in verapamil control incubations.
Plasma cyclosporin A concentrations
Plasma for the cyclosporin A trough assay was obtained immediately prior to the morning dose, and concentrations were determined by standard monoclonal antibody or fluorescent polarization radioimmunoassays at commercial laboratories. The results are presented as nanograms per milliliter of plasma.
Statistical analysis
Distributions at baseline and week 2 and week 4 laboratory values are summarized as median values and interquartile ranges (IQR). Exact Wilcoxon rank-sum and sign tests were used to compare the distribution of P-glycoprotein efflux changes from baseline between and within arms, respectively, and Spearman′s correlation was used to assess the association between efflux changes and cyclosporin A trough levels. The median-unbiased point estimate of the shift parameter between the two distributions and exact 95% confidence interval (CI) was estimated from the HodgesLehmann procedure. For example, a positive shift means efflux values from the cyclosporin A/ART arm are shifted lower than those in the ART-alone arm. Data on subjects who did not complete 2 weeks of cyclosporin A (in the cyclosporin A arm) and 4 weeks of ART were excluded from these analyses; the results presented are for the as-treated patient study population based on ART and cyclosporin A administration. Separate inference for changes from baseline to day 14 and day 28 was performed, and no adjustments were made for multiple comparisons across time.
Results
The analysis reported here involved 16 of the 42 participants in the A5138 study. The other 26 study participants were excluded because they either enrolled in A5138 before the P-glycoprotein study was initiated (n=16) or they were not in the as-treated study population (n=10). Baseline characteristics (age, race/ethnicity, sex, CD4 T cells, and plasma HIV-1 RNA) did not differ by group (nine individuals randomized to cyclosporin A/ART; seven to ART alone; Table 1 ), and they were similar to those of the other 26 participants (data not shown). Of the 16 participants, 14 had CD4 T cell P-glycoprotein assay data at day 14 (six in the cyclosporin A/ART arm; eight in the ART-alone arm), and 13 had assay data at day 28 (five and eight, respectively). Median baseline P-glycoprotein activities, expressed as the percentage of dye efflux-positive (dim) cells, within T cell subsets were: 23% in total CD4 T cells, 28% in naïve CD4 T cells, 47% in total CD8 T cells, and 76% in naive CD8 T cells.
Median baseline P-glycoprotein activity in total CD4 T cells was 24% in the cyclosporin A/ART arm and 22% in the ART alone arm (Fig. 2a) . Median changes from baseline to week 2 consisted of an 8 percentage point decrease in the cyclosporin A/ART arm (relative decrease of 42% in proportion of dim cells) and no change in the ART-alone arm (95% CI for shift in distributions 5-12 percentage points, P=0.001). At 28 days (2 weeks after discontinuing cyclosporin A and initiating efavirenz), median changes from baseline in CD4 T cell P-glycoprotein activity no longer differed between arms: in naïve CD4 T cells, median baseline P-glycoprotein activity was 28% in the cyclosporin A /ART arm and 33% in the ART alone arm. The median changes from baseline to week 2 were a 9 percentage point decrease in the cyclosporin A/ART arm, and no change in the ART alone arm ( Fig. 2b ; 95% CI for shift in distributions 3-22 percentage points, P=0.01). At 28 days, the median change from baseline in naïve CD4 T cell P-glycoprotein activity no longer differed between arms. In total and naïve CD8 T cells, there were no significant changes in Pglycoprotein activity from baseline to day 14 ( Fig. 2c, d) .
We next assessed correlations between day 14 trough plasma cyclosporin A concentrations and the change in Pglycoprotein activity from baseline to day 14. In total CD4 T cells, we found no significant correlation (Spearman′s rho = 0.00, P=1.00; Fig. 3a) , whereas in naïve CD4 T cells, there was an inverse correlation (−0.89, P=0.02; Fig. 3b ). In CD8 T cells, there was a trend toward an inverse correlation (−0.77, P=0.07), which in naive CD8 T cells reached statistical significance (−0.94, P=0.005; Fig. 3c, d ).
Discussion
The results of this study demonstrate that oral cyclosporin A inhibits peripheral blood T cell P-glycoprotein activity in HIV-infected adults and quantify the magnitude of this inhibition. An inhibitory effect was demonstrable on total CD4 T cells, less so on naïve CD4 T cells, and not at all on CD8 T cells (Fig. 2) . This difference among cell types may reflect the lower baseline P-glycoprotein activity on total CD4 T cells [41] , which potentially allows the detection of inhibition by cyclosporin A even at relatively low drug concentrations. This lower baseline P-glycoprotein activity would be consistent with the lack of observed correlation between cyclosporin A concentrations and P-glycoprotein inhibition in total CD4 T cells (Fig. 3a) . In contrast, a correlation was observed in naïve CD4 and CD8 T cell subsets ( Fig. 3b-d) , suggesting that the greater absolute Pglycoprotein activity in these cell populations may have made a concentration-dependent inhibition more demonstrable (i.e., only the highest cyclosporin A concentrations provided an inhibitory effect). It was notable that in the total CD4 T cell population (Fig. 3a) , all subjects had a >5% decrease in P-glycoprotein activity, regardless of the trough cyclosporin A concentration, without an apparent dose response. In contrast, in the naïve CD8 T cell subsets (with the greatest baseline P-glycoprotein activity), >5% decreases in P-glycoprotein activity were only seen in two subjects with the highest cyclosporin A trough concentrations (Fig. 3d) . We did not perform cyclosporin A doseresponse experiments using our assay. Previous studies have demonstrated full inhibition of P-glycoprotein function in lymphocytes when the study subjects were exposed to much higher concentrations of cyclosporin A than the trough levels observed in our subjects [43] . Importantly, the therapeutic regimen administered during the first 14 days ofthe ART regimen did not include PIs or NNRTIs, medications reported to inhibit and/or induce Pglycoprotein activity and which, therefore, could confound analyses focused on cyclosporin A. After day 14, all A5138 participants received efavirenz, which can induce Pglycoprotein expression under various conditions. Exposing a colon adenocarcinoma cell line to high concentrations of efavirenz for 3 days caused a twofold increase in P-glycoprotein expression but somewhat decreased Pglycoprotein activity [18] . In contrast, intestinal Pglycoprotein activity did not increase in rats that had been administered oral efavirenz for 6 days [45] . In our study, 14 days of efavirenz administration (days 14-28) did not markedly alter peripheral blood T cell P-glycoprotein activity in the ART-alone arm, although we cannot exclude a modest induction of P-glycoprotein by efavirenz following discontinuation of cyclosporin A. Recent data in cell culture [46, 47] and murine [48] models have suggested that abacavir may also serve as a P-glycoprotein substrate. However, zidovudine and lamivudine did not affect P-glycoprotein [47] . Although we cannot exclude an inhibitory effect of abacavir in this study, all subjects received the same dose of abacavir for the same length of time, and only as-treated data were included in analyses; therefore, any differences between groups would be most likely due to cyclosporin A exposure.
Our study has several limitations, and the results of the study should be considered preliminary. Since specimen collection for this study did not begin until after enrollment had started in the A5138 study, not all of the participants in the A5138 study were eligible for inclusion in this analysis. Demographics, CD4, and HIV-1 RNA levels at baseline did not differ between A5138 subjects included and not included in this analysis (data not shown). This study required the overnight shipment of specimens to the Pglycoprotein assay laboratory. Specimens assayed within 24 h at ambient temperature did not show substantial changes in efflux activity compared to fresh specimens (authors' unpublished data), but we cannot exclude additional effects resulting from overnight shipping. Certainly, the in vivo pharmacodynamics of these relationships are complicated and cannot be fully characterized by P-glycoprotein activity and cyclosporin A concentrations alone. Factors we did not assess in this study, such as other cellular drug transporters and hepatic metabolism, likely influence these relationships. Although PI-and NNRTI-sparing regimens are not currently recommended ART regimens in clinical practice, this study design provided a unique opportunity to investigate the effects of short-term cyclosporin A in this context, and the insights provided are relevant. Nonetheless, our data cannot be used to determine the effects of cyclosporin A or other P-glycoprotein inhibitors used for longer periods of time or with ART regimens containing ritonavir or other PIs. In addition, the absolute changes in P-glycoprotein efflux activity are small, and the clinical relevance of such changes is unknown. Finally, because of the small sample size in this study, there was not adequate statistical power to detect modest or moderate differences between all groups. The optimization of pharmacokinetic profiles of longterm ART remains a priority. Adjunctive pharmacologic manipulation is well established in HIV therapeutics, primarily that involving the targeted inhibition of CYP3A isoforms to enhance plasma exposure for PIs [49] . While cyclosporin A may not be well suited to this purpose because of its immunosuppressive properties, studies should continue to evaluate the targeted inhibition of Pglycoprotein and other drug transporters as well as the associated pharmacokinetic and clinical consequences. 
